US-based medical device company Luminex has secured the CE-IVD status under the European Directive on In-Vitro Diagnostic Medical Devices for its ARIES Flu A/B and RSV Assay.
The ARIES Flu A/B and RSV Assay is used to detect and classify mainly three respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) by examining nasopharyngeal swabs (NPS) specimens from patients exhibiting signs of respiratory tract infection.
Luminex Europe, the Middle East, Africa and India (EMEIA) managing director Thomas Pracht said: "The ARIES Flu A/B and RSV Assay provides a rapid, automated and cost-effective way to inform actionable treatment decisions and manage outbreaks in markets accepting CE marking for clinical use.
"Combined with our comprehensive respiratory test menu, we believe the ARIES Flu A/B and RSV Assay provides the most flexible and complete clinical algorithm for improved patient outcomes."
The polymerase chain reaction (PCR) based qualitative in vitro diagnostic test promotes laboratory efficiency, seamlessly integrating into the modern-age laboratory infrastructure while ensuring accurate results.
The internal barcode scanning and other advanced features installed into Aries helps reducing the possibility of operator errors.
Aries features two independent modules each support from one to six cassettes, which enables both STAT and batch testing of in-vitro diagnostic device (IVD) and homebrew assays using multicode reagents when using a common Universal Assay Protocol.
Its integrated touchscreen PC reduces the necessity of a separate computer peripherals including keyboard and mouse which subsequently increases bench space.
Image: The ARIES(R) Flu A/B and RSV Assay detects influenza virus. Photo: courtesy of PRNewsFoto / Luminex Corporation.
